Ultragenyx Pharmaceutical Inc. (RARE)
| Market Cap | 3.25B |
| Revenue (ttm) | 331.95M |
| Net Income (ttm) | -470.20M |
| Shares Out | 70.05M |
| EPS (ttm) | -6.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 80,688 |
| Open | 45.85 |
| Previous Close | 45.84 |
| Day's Range | 45.30 - 46.48 |
| 52-Week Range | 45.20 - 105.99 |
| Beta | 1.58 |
| Analysts | Buy |
| Price Target | 131.39 (+183.4%) |
| Earnings Date | May 5, 2022 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysacc...
Financial Performance
In 2021, RARE's revenue was $351.41 million, an increase of 29.66% compared to the previous year's $271.03 million. Losses were -$454.03 million, 143.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for RARE stock is "Buy." The 12-month stock price forecast is 131.39, which is an increase of 183.35% from the latest price.
News
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates
Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare a...
Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seriou...
Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update
NOVATO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio...
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report
NOVATO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio...
Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors
Physician researcher and biopharmaceutical executive to join R&D Committee Physician researcher and biopharmaceutical executive to join R&D Committee
Ultragenyx (RARE) Begins Dosing in Pivotal Study on Setrusumab
Ultragenyx (RARE) doses the first patient in a pivotal phase II/III study evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta.
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment ...
Global study will evaluate UX143 in pediatric and young adult patients ages 5 to
Ultragenyx to Participate in the Cowen Health Care Conference
NOVATO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...
Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates
Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.
Ultragenyx (RARE) Reports Q4 Loss, Lags Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -35.61% and 0.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories 1 of $192.6 million
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update
NOVATO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...
Regeneron (REGN) Collaborates With Ultragenyx for Evkeeza
Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.
Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Do...
Preliminary 2021 Crysvita revenue in Ultragenyx territories of $191 million to $193 million and Dojolvi revenue of $38 million to $40 million
Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference
NOVATO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serio...
Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference
NOVATO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serio...
Why Is Ultragenyx (RARE) Down 11.4% Since Last Earnings Report?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx (RARE) Begins Dosing in Phase I/II Study of UX053
Ultragenyx (RARE) doses the first patient in a phase I/II study evaluating its investigational mRNA candidate, UX053, for treating glycogen storage disease type III.
GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala
Overall GTX-102 program update on track for the end of 2021 Overall GTX-102 program update on track for the end of 2021
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of G...
NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...